Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation

Transplantation

Volumn 84, Issue 5, 2007, Pages 587-591

  Cotler, Scott J ^a,b   Kallwitz, Eric ^a   TenCate, Veronica ^a   Bhushan, Anita ^a   Berkes, Jamie ^a   Benedetti, Enrico ^a   Layden Almer, Jennifer ^a   Layden, Thomas J ^a   Valyi Nagy, Tibor ^a   Guzman, Grace ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MC 787 ^*  (United States)

Author keywords

Diabetes mellitus; Hepatitis C; Liver transplantation; Oxidative stress

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; HYDROXYL RADICAL; INDICATOR; INSULIN; PARAFFIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; FIBROSIS; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; STAINING; STATISTICAL SIGNIFICANCE; TISSUE INJURY; TISSUE SECTION;

BIOPSY; DEOXYGUANOSINE; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; SURVIVAL RATE; TIME FACTORS;

EID: 34548739696     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000279003.40279.0e     Document Type: Article

References (35)

1. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673.
2. Velidedeoglu E, Mange KC, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV-recipients. Transplantation 2004; 77: 1834.
3. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823.
4. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202.
5. Machicao VI, Bonatti H, Krishna M, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84.
6. Condron SL, Heneghan MA, Patel K, et al. Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation 2005; 80: 145.
7. Berenguer M, Prieto M, Cordoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28: 756.
8. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5(4 Suppl 1): S107.
9. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. Transplantation 2004; 77: 226.
10. Saab S, Shpaner A, Zhao Y, et al. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transplant 2006; 6: 1890.
11. Driscoll CJ, Cashion AK, Hathaway DK, et al. Posttransplant diabetes mellitus in liver transplant recipients. Prog Transplant 2006; 16: 110.
12. Soule JL, Olyaei AJ, Boslaugh TA, et al. Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients. Am J Surg 2005; 189: 552.
13. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592.
14. Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 1066.
15. AlDosary AA, Ramji AS, Elliott TG, et al. Post-liver transplantation diabetes mellitus: An association with hepatitis C. Liver Transpl 2002; 8: 356.
16. Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. Diabetes Care 2006; 29: 1096.
17. Aytug S, Reich D, Sapiro LE, et al. Impaired IRS-1/PI3-kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384.
18. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695.
19. Foxton MR, Quaglia A, Muiesan P, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006; 6: 1922.
20. Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006; 290: G847.
21. Gopaul NK, Anggard EE, Mallet AI, et al. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995; 368: 225.
22. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409.
23. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25: 658.
24. Demetris AJ, Adeyi O, Bellamy CO, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489.
25. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313.
26. Cui J, Holmes EH, Greene TG, Liu PK. Oxidative DNA damage precedes DNA fragmentation after experimental stroke in rat brain. Faseb J 2000; 14: 955.
27. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 34: 825.
28. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 2001; 98: 9599.
29. Abdalla MY, Ahmad IM, Spitz DR, et al. Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses. J Med Virol 2005; 76: 489.
30. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 2005; 7: 1040.
31. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000; 21: 49.
32. Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of rodent Kupffer cells on stellate cells. Hepatology 2006; 44: 1487.
33. Sugimoto R, Enjoji M, Kohjima M, et al. High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver Int 2005; 25: 1018.
34. Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 51.
35. Marchetti P. New-onset diabetes after liver transplantation: From pathogenesis to management. Liver Transpl 2005; 11: 612.